Reporter brief
Fisetin plus exercise versus placebo in breast cancer survivors for frailty prevention: phase II RCT
What happened
This phase II randomized controlled trial tested fisetin (a dietary compound found in strawberries) combined with exercise against placebo for preventing frailty in breast cancer survivors. The trial was designed to evaluate whether fisetin could eliminate senescent cells—aged cells that stop dividing but persist in tissues—which are hypothesized to contribute to frailty through inflammatory pathways.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Breast cancer survivors
- Design
- Rct
- Sample
- —
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 30, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.